Properties of second-generation oral anti-HCV agent classes [8,10,59].

<p>+ indicates low level, ++ indicates moderate level, +++ indicates high level, and - indicates unknown level. US Food and Drug Administration license dates current as of 31 December 2014.</p><p>Abbreviations: NS, nonstructural protein.</p><p>Properties of second-generation oral anti-HCV agent classes [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001795#pmed.1001795.ref008" target="_blank">8</a>,<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001795#pmed.1001795.ref010" target="_blank">10</a>,<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001795#pmed.1001795.ref059" target="_blank">59</a>].</p

Number of deaths due to major communicable diseases in 2013 [4].

<p>Viral hepatitis deaths include those related to acute viral hepatitis, liver cancer secondary to hepatitis B and hepatitis C, and cirrhosis of the liver secondary to hepatitis B and hepatitis C.</p

Flow diagram.

<p>Flow diagram.</p

Characteristics of studies presenting data on the proportion of people living with HIV who tested TST-positive stratified by CD4 cell counts.

*<p>Denotes median age.</p><p>“…” denotes information not stated.</p><p>TU = tuberculin units; PPD = purified protein derivative; STD = sexually transmitted disease; MSM = men who have sex with men;</p><p>IDU = people who inject drugs; ART = antiretroviral therapy; IPT = isoniazid preventive therapy.</p

Forest plot showing the proportions (%, 95%CI) of people living with HIV testing TST-positive in the all studies (n = 19) with data grouped according to: a) geographical region; b) country TB prevalence (<100, 100–249 and ≥250 cases per 100,000 population) and c) CD4 cell count (<200 or ≥200 cells/µL).

<p>Forest plot showing the proportions (%, 95%CI) of people living with HIV testing TST-positive in the all studies (n = 19) with data grouped according to: a) geographical region; b) country TB prevalence (<100, 100–249 and ≥250 cases per 100,000 population) and c) CD4 cell count (<200 or ≥200 cells/µL).</p

Forest plot showing the proportions (%, 95%CI) of people living with HIV testing TST-positive in studies (n = 5) included in the meta-analysis with data grouped according to CD4 cell count strata (<200, 200–499 and ≥500 cells/µL).

<p>The median proportions testing positive in these three groups were 12.4% (range, 8.2–15.3%), 28.4% (range, 20.1–36.9%) and 37.4% (range, 31.3–56.3%). The I² statistics for these three groups of data were 54.4% (P = 0.067), 84.2% (P<0.001) and 86.8% (P<0.001), respectively.</p

Treatment categories and regimens under Revised National TB programme, India.

<p>PTB = Pulmonary Tuberculosis; EPTB = Extrapulmonary Tuberculosis; H = Isoniazid; R = Rifampicin; Z = Pyrazinamide; E = Ethambutol; Km = Kanamicin; Lvx = Levofloxacin; Eto = Ethionamide; Cs = Cycloserine.</p><p>The number before the letters indicates number of months of treatment; numbers in subscript indicate the number of days per week of doses.</p>*<p>Seriously ill includes patients that have military TB, extensive parenchymal infiltration, co-infection with HIV, cavitary disease. In children, seriously ill sputum smear-negative PTB includes all forms of sputum smear-negative PTB other than primary complex. Seriously ill EP-TB includes TB meningitis (TBM), disseminated TB, TB pericarditis, TB peritonitis and intestinal TB, bilateral extensive pleurisy, spinal TB with or without neurological complications, genitourinary TB, and bone and joint TB.</p>**<p>Not seriously ill sputum smear-negative PTB includes primary complex. Not seriously ill EP-TB includes lymph node TB and unilateral pleural effusion.</p>***<p>The dosage strengths are as follows: H : Isoniazid (600 mg), R:Rifampicin (450 mg), Z: Pyrazinamide (1500 mg); E: Ethambutol (1200 mg); S: Streptomycin (750 mg).</p>****<p>MDR-TB diagnosis is done through culture and drug sensitivity testing from a quality-assured laboratory. Treatment of MDR-TB uses a standardized regimen, comprising of 6 drugs – Km (Kanamycin), Lvx (levofloxacin), Eto (Ethionamide), Z (pyrazinamide), E (Ethambutol) and Cs (Cycloserine) during 6–9 months of intensive phase and 4 drugs (Lvx, Eto, E and Cs) during the 18 months of continuation phase. Dosages of drugs are based on three weight bands (16–25 kg, 26–45 Kg, and >45 Kg).</p

Magnitude of selected NCDs and their risks factors in Malawi: July to September 2009.

<p>BP =  Blood Pressure, CI =  Confidence interval, FBS =  Fasting blood glucose, n =  number of participants in the group, *statistically significant, p<0.05; male vs female, urban vs rural.</p

Characteristics of participants enrolled in Malawi NCD STEPS survey compared to National Statistics Office (NSO) 2008 population figures.

<p>§Marital status NSO data includes those aged ≥65, *statistically significant, p<0.05, survey male participants vs NSO male population figures, #No comparable NSO data on education, n =  number in the group, CI =  confidence interval.</p

Flow Chart showing sputum smear examination at end of intensive phase and end of treatment in new smear negative pulmonary tuberculosis patients in Delhi, India (2009).

<p>Flow Chart showing sputum smear examination at end of intensive phase and end of treatment in new smear negative pulmonary tuberculosis patients in Delhi, India (2009).</p